76 search results for: disease control
The Benefits of Early Intervention in AD: More Than Skin Deep
Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
Describing Disease Control in PN
Dr. Chovatiya discusses PN, emphasizing that while itch is a major symptom, the disease's burden is multi-dimensional, affecting appearance, sleep, social life, and mental health, requiring comprehensive therapeutic solutions.
ERS-ISIAN 2025 | Type 2 Inflammation: Links with Severe/Uncontrolled CRSwNP
Prof. Vibeke Backer provides an insightful presentation on the association of type 2 inflammation and the pathogenesis and management of severe and uncontrolled CRSwNP.
EAACI 2025 | At The Intersection of the Type 2 Airways: Navigating the Challenges of CRSwNP & Co-existing Asthma
Professors Brian Lipworth, Zuzana Diamant, and Philippe Gevaert delve into the complexities of managing patients with both severe and/or uncontrolled CRSwNP and co-existing asthma through an evaluation of the diagnostic challenges, personalized treatment strategies, and the latest advancements in understanding the interconnected pathophysiology of these type 2 airway diseases.
Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP
In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Vibeke Backer discusses how Type 2 inflammation drives severe, uncontrolled CRSwNP. It covers key immune cells and biomarkers (e.g., IL-4, IL-5, IL-13, TSLP), global prevalence differences, and the importance of symptom tracking and targeted therapies.
Disease Modification Concepts in AD
Dr. Ramien explores the concept of disease modification in AD focusing on disease control, and the prevention or slowing of development of atopic comorbidities.
Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Amy Paller reviews a Japanese study showing that early proactive treatment of infant atopic dermatitis with topical corticosteroids reduced the incidence of food allergy but was also associated with decreased gains in height and weight.
What do we mean by disease control in AD?
Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.
The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?
Professors Bouaziz, Paller, and Irvine discuss the clinical burden of atopic dermatitis, the biomarkers of subclinical control, and evidence of potential disease modification in AD at EADV 2025.
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.
Pediatric Asthma Patient Case Tool: Ash
Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients
On-Treatment Clinical Remission in Asthma Patients Case Tool
Review a severe asthma patient case to learn more about assessing asthma control and on-treatment clinical remission.
